Nucleic acid-lipid nanoparticle composition, and lyophilized preparation thereof, preparation method therefor and use thereof
By using lyophilized protective agents such as lactate and buffer in mRNA vaccines, the problem of poor storage stability of mRNA vaccines is solved, and long-term stability and biological activity are achieved at refrigeration or room temperature are reduced, and production and transportation costs are reduced.
Patent Information
- Application Number
- PCT/CN2023/130039
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-02
- Filing Date
- 2023-11-07
- Publication Date
- 2024-12-05
AI Technical Summary
The existing mRNA vaccines have poor storage stability, require ultra-low temperature storage, and have a short validity period, which leads to difficulties in storage, transportation and distribution, especially the rapid reduction of integrity and activity of lyophilized preparations at room temperature or high temperatures.
Using lactate, such as sodium lactate, as a lyophilized protective agent, combined with buffer and lyophilized protective agent, optimizes the lyophilized process, reduces moisture activity, improves the lyophilized stability of nucleic acid-lipid nanoparticles, and makes them refrigerated. Or it can be stored for a long time at room temperature to extend the validity period.
It significantly improves the stability and biological activity of the lyophilized preparation of mRNA vaccine, extends storage time, reduces production costs and transportation difficulty, and ensures the integrity of the preparation and cell transfection efficiency.
Smart Images

Figure CN2023130039_05122024_PF_FP_ABST
Abstract
Description
Nucleic acid-lipid nanoparticle composition, freeze-dried preparation, preparation method and application thereof Technical Field
[0001] The present invention belongs to the field of biomedicine technology and relates to a nucleic acid-lipid nanoparticle composition, a lyophilized preparation of the composition, and a preparation method and application thereof. Background Art
[0002] During the COVID-19 outbreak, mRNA vaccines have the advantages of safety, high immune response, and low production costs, and have been approved for emergency marketing in the United States and the European Union. In recent years, studies have found that transient protein expression induced by mRNA has great application value in many fields such as other infectious disease vaccines, cancer vaccines, cardiovascular diseases, protein replacement therapies, and genetic diseases. It can even achieve autonomous production of CAR-T effects through in vivo injection. However, unlike the storage conditions of most vaccines (2-8°C), the mRNA vaccines currently on the market have poor long-term stability and need to be stored at ultra-low temperatures (-20°C, even -70°C), and their shelf life is less than 6 months. Faced with the need to store, transport, and distribute hundreds of millions of doses of mRNA vaccines around the world, stability has become a bottleneck issue in its application.
[0003] mRNA chains range from 1,000 to 5,000 bases in length. Early studies have shown that naked mRNA is rapidly hydrolyzed by ribonucleases (RNases). RNases are ubiquitous, attaching to large quantities both inside and outside the body and requiring special treatment for removal. Furthermore, just a single change in the mRNA chain (bond breakage or base oxidation) can terminate translation, making the integrity of the mRNA molecule crucial in mRNA vaccines.
[0004] The expression of mRNA into target proteins in vivo requires complete mRNA molecules. Only one change in the long mRNA chain (bond breaking or base oxidation) will result in the inability to translate, so the integrity of the mRNA molecules in mRNA preparations is crucial. At the same time, studies by Fabre et al. have shown that under the same conditions, the rate of decrease in the integrity of mRNA molecules is positively correlated with the length of the mRNA molecule chain. The longer the mRNA molecule chain, the more likely it is to have its integrity reduced during storage. The two mRNA COVID-19 vaccines currently on the market have mRNA molecule chains of approximately 4,000 bases in length, while the self-replicating mRNA molecules under clinical development can even reach more than 10,000 bases in length. It is even more urgent to slow down the rate of decrease in the integrity of such mRNA molecules.
[0005] Lyophilizing mRNA preparations is an effective means of improving their stability, and some studies have examined this approach. In 2009, Mutzke, TM, et al. from CureVac invented a patent for mRNA lyophilization titled "LYOPHILIZATION OF NUCLEIC ACIDS IN LACTATE-CONTAINING SOLUTIONS." This patent describes a process for preparing a lyophilized mRNA preparation using CureVac's proprietary protamine-mRNA complex. The patent describes a method for preparing an mRNA solution using 80% lactated Ringer's solution. The mRNA solution is then mixed with protamine in a 4:1 (w / w) ratio, and the resulting mRNA-protamine complex is lyophilized. The lyophilized mRNA preparation exhibits improved integrity after being stored at room temperature. The principle behind this approach is that the presence of 80% lactated Ringer's solution influences the complexing between protamine and mRNA, forming a more stable structure that maintains good stability at room temperature even after lyophilization.
[0006] Since lactated Ringer's solution is a salt-rich solvent, existing technologies are generally considered unsuitable for lipid nanoparticle freeze-drying. The reason is that nucleic acid-lipid nanoparticles containing high salt concentrations will be destroyed after freeze-drying. CureVac's good freeze-drying using lactated Ringer's solution as a solvent cannot be replicated in nucleic acid-lipid nanoparticle preparations.
[0007] In 2022, Muramatsu et al. (in collaboration with BioNTech) also published an article announcing the long-term storage stability of their mRNA freeze-dried preparations. After being placed at 4°C for 24 weeks, the quality indicators of the mRNA-LNP freeze-dried preparations changed little, and the in vivo biological activity did not decrease significantly, which was significantly improved compared to the stability of liquid frozen preparations. After the freeze-dried preparations were placed at 25°C or 42°C, the integrity and in vivo activity of the preparations showed a certain downward trend. After the freeze-dried preparations of the two shorter mRNA sequences Luc mRNA and PR8HA mRNA sequences in the article were placed at 42°C for one month, the integrity dropped sharply from the initial 100% to between 30-40%. Correspondingly, the mouse immune antibody titer was 1-2 orders of magnitude lower than the initial level. This reflects that even for freeze-dried preparations, when stored at room temperature or higher temperatures, the integrity will be significantly reduced in the short term, and the reduction in integrity is closely related to the weakening of in vivo activity.
[0008] In order to improve the stability of mRNA preparations, existing technologies prepare them into freeze-dried preparations to reduce the occurrence of hydrolysis. However, even after being prepared into freeze-dried preparations, the final preparation still contains at least 1-2% of water, which is difficult to completely remove. This part of water can still cause mRNA hydrolysis.
[0009] Therefore, there is an urgent need for new lyophilized preparations that can better avoid mRNA hydrolysis than existing technologies, thereby obtaining mRNA preparations with higher stability.
[0010] Summary of the Invention
[0011] The first objective of the present disclosure is to improve the storage stability of nucleic acid-lipid nanoparticles by reducing storage conditions to refrigeration (2-8°C) or room temperature (10-30°C). This, in turn, extends their shelf life. Furthermore, they can be rapidly rehydrated, allowing them to last for over 18 months in cold storage and over 12 months at room temperature.
[0012] The second purpose of the present disclosure is to significantly shorten the total duration of the freeze-drying process, improve efficiency, and reduce energy and time costs of production.
[0013] The third objective of the present disclosure is to screen specific types and amounts of lyoprotectants for nucleic acid-lipid nanoparticles to fully maintain the total amount, encapsulation efficiency and integrity of the lyophilized rehydrated preparation of the nucleic acid-lipid nanoparticles, while maintaining the biological activity in vivo and in vitro without loss.
[0014] The fourth purpose of the present disclosure is to break through the "empirical" development model of the freeze-drying process and establish a method for evaluating key physical and chemical properties.
[0015] The present disclosure is based on the inventors' surprising discovery that, although it is generally believed in the prior art that the introduction of salts is detrimental to the freeze-drying of lipid nanoformulations, the addition of lactate, such as sodium lactate, to nucleic acid-lipid nanoparticle formulations can improve the stability of nucleic acid-lipid nanoparticles after freeze-drying, thereby completing the present invention.
[0016] In one aspect, the present disclosure provides a nucleic acid-lipid nanoparticle composition comprising the following components: a nucleic acid, a lipid and lactate, wherein the lactate is selected from sodium lactate or potassium lactate and has an amount of 5-100 mM, such as 5-75 mM, 5-50 mM or 10-100 mM, preferably 5-50 mM.
[0017] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises a buffer, wherein the ratio of the buffer to lactate is 0.25-1:1.
[0018] In some embodiments, the buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer, and tris buffer. The content of the buffer is 1.25-100 mM, such as 2.5-100 mM, 5-100 mM, 5-75 mM, or 5-50 mM. Preferably, the content of the buffer is 1.25-50 mM, or 5-50 nM.
[0019] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises a lyoprotectant.
[0020] In some embodiments, the lyoprotectant is selected from a combination of one or more of the group consisting of sucrose, trehalose, lactose, cyclodextrin, and mannitol.
[0021] In some embodiments, the pH of the nucleic acid-lipid nanoparticle composition is 1.0-14.0, preferably 5.0-9.0, and more preferably 7.0-8.0.
[0022] In some embodiments, the nucleic acid is selected from the group consisting of ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, ployI:C, SamRNA and 5'-pppRNA.
[0023] In some embodiments, the nucleic acid is encapsulated in lipid nanoparticles (LNPs).
[0024] In some embodiments, the lipids include cationic lipids, neutral phospholipids, PEG-lipids, and optionally steroidal lipids.
[0025] In some embodiments, the composition is further prepared as a lyophilized formulation.
[0026] In some embodiments, the solid content of the lactate is 0.5-10.0 wt%, such as 0.5-7.5 wt%, 0.5-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%, based on the total weight of the lyophilized formulation.
[0027] In some embodiments, the solid content of the buffer is 0.35-10.0 wt%, such as 0.35-7.5 wt%, 0.35-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%, based on the total weight of the lyophilized formulation.
[0028] In another aspect, the present disclosure provides a method for preparing a nucleic acid-lipid nanoparticle composition, wherein the composition is prepared as a lyophilized preparation, and the preparation method comprises the following steps:
[0029] (1) Mixing the lactate solution with the nucleic acid-lipid nanoparticle stock solution, or
[0030] Add lactate to the nucleic acid solution before nucleic acid encapsulation, followed by lipid addition, or
[0031] During the ultrafiltration and fluid exchange phase of nucleic acid-lipid nanoparticles, a lactate-containing solution was used for ultrafiltration.
[0032] Wherein, the lactate is selected from sodium lactate or potassium lactate, and the content is 5-100mM, such as 5-75mM, 5-50mM or 10-100mM, preferably 5-50mM;
[0033] (2) adding a lyoprotectant; and
[0034] (3) freeze-drying to obtain a freeze-dried preparation of the nucleic acid-lipid nanoparticle composition.
[0035] In some embodiments, the lyoprotectant is selected from a combination of one or more of the group consisting of sucrose, trehalose, lactose, cyclodextrin, and mannitol.
[0036] In some embodiments, the solid content of the lyoprotectant is 50-99.9 wt % based on the total weight of the lyophilized formulation.
[0037] In some embodiments, step (1) further comprises adding a buffer, wherein the ratio of the buffer to lactate is 0.25-1:1.
[0038] In some embodiments, the buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer, and tris buffer. The content of the buffer is 1.25-100 mM, such as 2.5-100 mM, 5-100 mM, 5-75 mM, or 5-50 mM. Preferably, the content of the buffer is 1.25-50 mM, or 5-50 nM.
[0039] In some embodiments, the pH of the solution prepared in step (1) is 1.0-14.0, such as 2.0-13.0, preferably 5.0-9.0, and preferably 7.0-8.0.
[0040] In some embodiments, the nucleic acid is selected from the group consisting of ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, ployI:C, SamRNA and 5'-pppRNA.
[0041] In some embodiments, in step (1), the nucleic acid is encapsulated in lipid nanoparticles.
[0042] In some embodiments, the lipids include cationic lipids, neutral phospholipids, PEG-lipids, and optionally steroidal lipids.
[0043] In yet another aspect, the present disclosure provides use of the nucleic acid-lipid nanoparticle composition of the present disclosure in the preparation of a medicament.
[0044] In some embodiments, the medicament is a vaccine.
[0045] In some embodiments, the vaccine is a vaccine for the prevention of cancer, a therapeutic tumor vaccine, a viral infection, a bacterial infection, or a fungal infection.
[0046] In some embodiments, the virus is selected from the group consisting of norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, poliovirus, rabies virus, and rotavirus.
[0047] In some embodiments, the drug is an oral formulation, an intramuscular injection formulation, a subcutaneous injection formulation, an intravenous injection formulation, or an inhaled formulation.
[0048] In some embodiments, the inhalation formulation is a nebulized inhaler or a dry powder inhaler.
[0049] Compared with the prior art, the present disclosure has the following beneficial effects:
[0050] In order to solve the problem of mRNA hydrolysis caused by residual water in existing freeze-dried preparations, it is considered to introduce additives that can reduce the activity of water molecules to reduce the occurrence of mRNA molecular hydrolysis in freeze-dried preparations. Lactate, such as sodium lactate, is a naturally occurring, safe and non-toxic substance. It can further improve the stability of mRNA molecules in freeze-dried preparations by reducing water activity.
[0051] The present disclosure overcomes the prior art understanding that the introduction of salts can hinder the freeze-drying of lipid nanoformulations. The present disclosure addresses the issue of adding lactate, such as sodium lactate, alone to the freeze-drying of nucleic acid-lipid nanoparticles to improve their stability after lyophilization. The present disclosure also addresses the issue of compounding lactate with a buffer solution to further enhance the stability of nucleic acid-lipid nanoparticles after lyophilization.
[0052] The nucleic acid-lipid nanoparticles prepared in the present invention have significantly improved stability after freeze-drying compared to previously reported freeze-dried preparations. Their integrity remains at a high level after being placed at a high temperature of 42°C, and their in vivo activity is still well maintained. This can increase the storage temperature and extend the shelf life of the nucleic acid-lipid nanoparticle freeze-dried preparation, while significantly reducing storage and transportation costs.
[0053] The nucleic acid-lipid nanoparticles disclosed herein have good freeze-drying properties. The quality indicators of the freeze-dried preparation, such as appearance, reconstitution time, residual moisture, particle size, potential, encapsulation efficiency, mRNA content, and integrity, are not significantly changed compared with those before freeze-drying. The cell transfection efficiency and in vivo activity of the freeze-dried and reconstituted preparation are comparable to those before freeze-drying.
[0054] The present disclosure found that the freeze-drying stability of nucleic acid-lipid nanoparticles is closely related to the pH of the nucleic acid-lipid nanoparticles before freeze-drying. The present disclosure found that the pH of nucleic acid-lipid nanoparticles before freeze-drying should be maintained at 2-13, preferably, between 7-8 is more appropriate.
[0055] Adding lactate to the freeze-dried mRNA-LNP preparation significantly improves the stability of the currently reported mRNA-LNP freeze-dried preparation. The integrity remains at a high level after being placed at a high temperature of 42°C, and the in vivo activity is still maintained well. This can increase the storage temperature of the mRNA-LNP freeze-dried preparation and extend the shelf life, while significantly reducing storage and transportation costs.
[0056] The present disclosure adds lactate to a lyophilized mRNA-LNP preparation. Although prior art suggests that the introduction of salt is detrimental to the lyophilization of nanoformulations such as LNPs, the present disclosure, through screening for an appropriate dosage and method of addition, enables the mRNA-LNP to be well lyophilized after the addition of lactate. Quality indicators such as the appearance, reconstitution time, residual moisture, particle size, potential, encapsulation efficiency, mRNA content, and integrity of the lyophilized preparation do not significantly change compared to those before lyophilization. The cell transfection efficiency and in vivo activity of the lyophilized and reconstituted preparation are comparable to those before lyophilization.
[0057] The present disclosure can shorten the total freeze-drying process time of nucleic acid-lipid nanoparticles to 8 to 18 hours, significantly reducing energy consumption and the time cost of product scale-up production. Moreover, the freeze-dried nucleic acid-lipid nanoparticles prepared by the freeze-drying process of the present disclosure are quickly rehydrated (within 10 seconds), with high total nucleic acid content, encapsulation efficiency and nucleic acid integrity. In addition, the cell transfection efficiency of the preparation after freeze-drying and rehydration is not significantly different from that of the unfreeze-dried nucleic acid-lipid nanoparticle stock solution, and the in vivo immune response is high, even exceeding that of the unfreeze-dried nucleic acid-lipid nanoparticle stock solution. In addition, by reducing or even removing the aqueous microenvironment in the system through freeze-drying, the nucleic acid hydrolysis reaction catalyzed by nucleases can be inhibited, significantly improving the long-term stability of nucleic acid-lipid nanoparticles, extending the shelf life, and increasing the storage temperature to 2 to 8°C, significantly reducing the cost and efficiency of storage and transportation. In addition, the phase of the preparation of nucleic acid-lipid nanoparticles is converted from liquid to solid, which provides a possibility for the development of its new solid preparation, which is of great significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0058] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0059] FIG1 shows the cryo-electron microscopy results of Example 1-1 mRNA-LNP preparation after freeze-drying and reconstitution.
[0060] FIG2 a shows the integrity measurement spectrum of Example 2-1 after lyophilization and reconstitution.
[0061] FIG2 b shows the integrity measurement profile of Example 2-2 after lyophilization and reconstitution.
[0062] FIG2 c shows the integrity measurement profile of Example 2-3 after lyophilization and reconstitution.
[0063] FIG3 shows the changes in integrity of three groups of freeze-dried preparations of Example 2-1, Example 2-2, and Example 2-3 when stored at 42°C.
[0064] FIG4 a shows the integrity measurement profile of Example 2-4 after lyophilization and reconstitution.
[0065] FIG4 b shows the integrity measurement profile of Example 2-5 after lyophilization and reconstitution.
[0066] FIG4 c shows the integrity measurement profile of Example 2-6 after lyophilization and reconstitution.
[0067] FIG5 shows the expression of gE protein after mRNA-LNP transfection into cells.
[0068] FIG6 shows the cellular immunity level (Elispot) of mice after two immunizations.
[0069] FIG7 shows the humoral immune response levels of mice 14 days after the primary immunization and 14 days after the secondary immunization.
[0070] FIG8 shows the cell expression of different types of eGFP sequence mRNA before and after freeze-drying.
[0071] FIG9 shows the cryo-electron microscopy results of the mRNA-LNP preparation of Example 6-1 after freeze-drying and reconstitution.
[0072] FIG10 shows the cryo-electron microscopy results of Example 6-2 mRNA-LNP formulation after freeze-drying and reconstitution.
[0073] FIG11 shows the cell expression of eGFP mRNA sequences encapsulated by different protonatable cationic lipids before and after lyophilization.
[0074] FIG12 shows the cryo-electron microscopy results of the mRNA-LNP preparation of Example 7-1 after freeze-drying and reconstitution.
[0075] FIG13 shows the cryo-electron microscopy results of the mRNA-LNP preparation of Example 7-2 after freeze-drying and reconstitution.
[0076] FIG14 shows the cryo-electron microscopy results of Example 7-3 mRNA-LNP formulation after freeze-drying and reconstitution. DETAILED DESCRIPTION
[0077] The above and other objects, components and advantages will become apparent from the following more detailed description of specific embodiments, as illustrated and exemplified in the accompanying drawings, in which like reference numerals, symbols, etc. represent like parts, components or features of the specific embodiments. It should be noted that any process not specifically described below is readily understood or comprehensible to one skilled in the art with reference to the prior art. Reagents or instruments used without manufacturer designation are deemed to be commercially available conventional products.
[0078] In terms of their scope of use, the terms "comprises," "comprising," and "having," or any variations thereof, as used in the claims and description herein, will be considered to indicate an open group that may include unspecified other elements. The terms "at least one" and "one or more" can be used interchangeably. The term "single" is used to indicate one and only one of something. Similarly, when a specific number of things is required, other specific integer values, such as "two," will be used. The terms "preferably," "preferred," "preferably," "optionally," "may," and similar terms are used to indicate that the cited item, condition, or step is an optional (i.e., not required) feature in the embodiment. Unless otherwise stated, a range described as "between a and b" includes the values of "a" and "b."
[0079] Although various improvements have been described herein with reference to specific embodiments of the invention, it should be understood that such description is by way of illustration only and should not be construed as limiting the scope of any claimed invention. Accordingly, the scope and content of any claimed invention will be limited solely by the terms of the appended claims in their current form or as amended during prosecution or as implemented in any continuation application. Furthermore, it should be understood that, unless otherwise indicated, features of any specific embodiment discussed herein may be combined with one or more features of any one or more embodiments otherwise discussed or contemplated herein.
[0080] definition
[0081] As used herein, the term "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form, and includes DNA, RNA, and hybrids or derivatives thereof, such as double-stranded RNA, single-stranded RNA, isolated RNA (such as partially purified RNA), substantially pure RNA, synthetic RNA, recombinantly produced RNA, and altered RNA that differs from naturally occurring RNA by addition, deletion, substitution, and / or change of one or more nucleotides. Such alterations may include, for example, the addition of non-nucleotide substances to the ends or interior of an interfering RNA (e.g., at one or more nucleotides of the RNA). The nucleotides in the RNA molecules of the present invention may also include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs may be referred to as analogs or analogs of naturally occurring RNA. As used herein, the terms "ribonucleic acid" and "RNA" refer to molecules containing at least one ribonucleotide residue, including siRNA, antisense RNA, single-stranded RNA, microRNA, mRNA, non-coding RNA, and multivalent RNA. Ribonucleotides are nucleotides having a hydroxyl group at the 2' position of the β-D-ribofuranose moiety. These terms include double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), isolated RNA (such as partially purified RNA), substantially pure RNA, synthetic RNA, recombinantly produced RNA, and modified and altered RNA that differs from naturally occurring RNA by addition, deletion, substitution, modification, and / or change of one or more nucleotides. Alterations to RNA may include, for example, the addition of non-nucleotide substances to the ends or interior of an interfering RNA (e.g., at one or more nucleotides of the RNA), and nucleotides in the RNA molecule include non-standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs may be referred to as RNA analogs.
[0082] As used herein, the term "lipid nanoparticle" refers to a particle with at least one nanometer-scale size comprising at least one lipid, which is a lipid formulation that can be used to deliver therapeutic nucleic acids (e.g., mRNA) to a target site of interest (e.g., cells, tissues, organs, etc.). In some embodiments, the lipid nanoparticle is a nucleic acid-lipid particle, which is typically composed of a nucleic acid, a cationic lipid, a non-cationic lipid (e.g., a phospholipid), a binding polymer lipid (e.g., PEG-lipid) and an optional structural lipid (e.g., cholesterol) that prevents particle aggregation. Typically, therapeutic nucleic acids (e.g., mRNA) can be encapsulated in the lipid portion of a lipid nanoparticle, thereby protecting it from enzymatic degradation, which may also be referred to as a "nucleic acid-lipid nanoparticle."
[0083] As used herein, the term "lipid" refers to a class of organic compounds that are derivatives of fatty acids (e.g., esters) and are generally characterized by being insoluble in water but soluble in many organic solvents. Lipids are generally divided into at least three categories: (1) "simple lipids," which include fats and oils, as well as waxes; (2) "complex lipids," which include phospholipids and glycolipids; and (3) "derivative lipids," such as steroids.
[0084] As used herein, the terms "cationic lipid" and "ionizable lipid" are used interchangeably herein to include lipids and salts thereof having one, two, three or more fatty acids or fatty alkyl chains and a pH titratable amino head group (e.g., alkylamino or dialkylamino head group). Cationic lipids are typically protonated (i.e., positively charged) at a pH lower than the pKa of the cationic lipid and are substantially neutral at a pH higher than the pKa. Cationic lipids of the present invention may also be referred to as titratable cationic lipids.
[0085] As used herein, the term "phospholipid" refers to a lipid molecule consisting of two hydrophobic fatty acid "tails" and a hydrophilic "head" consisting of a phosphate group. These two components are most often bound together by a glycerol molecule, and therefore, in the present disclosure, the phospholipid is preferably a neutral phospholipid. In addition, the phosphate group is often modified by a simple organic molecule such as choline (i.e., to produce phosphocholine) or ethanolamine (i.e., to produce phosphoethanolamine). In some embodiments, the phospholipid can be selected from the following group, which includes but is not limited to: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPPC), C), 1,2-di-undecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholestyrene hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-bisdocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin and mixtures thereof.
[0086] As used herein, the term "polymer lipid" mainly includes PEG lipids, or alternatively referred to as PEGylated lipids, PEG-lipids (polyethylene glycol lipids), refers to any suitable lipid modified with a PEG (polyethylene glycol) group. In some embodiments, PEG lipids can be selected from the following group, including but not limited to PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and mixtures thereof. In some embodiments, the specific examples of PEG lipids include but are not limited to C14-PEG2000 (1,2-dimyristoyl-rac-glycerol, methoxypolyethylene glycol -2000 (DMG-PEG2000)) and C18-PEG5000 (1,2-distearoyl-rac-glycerol, methoxypolyethylene glycol -5000 (DSG-PEG5000)).
[0087] As used herein, the term "steroidal lipid", which may also be referred to as "structured lipid", refers to a steroidal compound (also referred to as sterol, steroid in some cases) or a lipid containing a steroidal moiety.
[0088] As used herein, the term "lyoprotectant" is used to increase the chemical and / or physical stability of a lipid compound or composition, such as lipid nanoparticles, during freeze-drying, storage, or reconstitution. In some embodiments, the lyoprotectant is selected from a sugar, a polyol, or a derivative thereof. In some embodiments, the lyoprotectant is selected from a monosaccharide, a disaccharide, or a mixture thereof. For example, the lyoprotectant can be sucrose, lactulose, trehalose, lactose, glucose, maltose, mannitol, cellobiose, cyclodextrin, or a mixture thereof. It should be noted that the lyoprotectant used in the present disclosure can be a lyoprotectant that is well known and commonly used by those skilled in the art and is not particularly limited in the present disclosure.
[0089] The term "vaccine" in this disclosure refers to a composition suitable for use in animals (including humans) that, upon administration, induces an immune response strong enough to minimally help prevent, ameliorate or cure clinical diseases resulting from infection by microorganisms.
[0090] The term "delivery system" in the present disclosure refers to a preparation or composition that regulates the spatial, temporal and dosage distribution of a biologically active ingredient in an organism.
[0091] Nucleic acid-lipid nanoparticles
[0092] Nucleic acids are encapsulated in the lipid portion of lipid nanoparticles to obtain nucleic acid-lipid nanoparticles.
[0093] In some embodiments, the nucleic acid includes but is not limited to ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, polyI:C, SamRNA or 5'-pppRNA. In some specific embodiments, the nucleic acid is mRNA.
[0094] In some embodiments, lipid comprises cationic lipid, neutral phospholipid, PEG-lipid and optional steroid lipid.For example, in some embodiments, lipid comprises cationic lipid, neutral phospholipid and PEG-lipid.In some embodiments, lipid comprises cationic lipid, neutral phospholipid, PEG-lipid and steroid lipid.
[0095] In some embodiments, the cationic lipid comprises an ionizable tertiary amine (e.g., pH titratable) head group; a C18 alkyl chain, wherein each alkyl chain independently has 0 to 3 (e.g., 0, 1, 2, or 3) double bonds; and an ether, ester, or ketal bond between the head group and the alkyl chain. Such cationic lipids include, but are not limited to, DSDMA, DODMA, DLinDMA, DLenDMA, γ-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DMA, DLin-K-C4-DMA, DLen-C2K-DMA, γ-DLen-C2K-DMA, DLin-MC2-DMA (also known as MC2), DLin-MC3-DMA (also known as MC3), DLin-MP-DMA (also known as 1-B11), and ALC-0315.
[0096] In some embodiments, the cationic lipid has the following structure:
[0097] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0098] G 1 and G 2 Each independently is an unsubstituted C6-C 10 alkylene;
[0099] G 3 For unsubstituted C1-C 12 alkylene;
[0100] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0101] R 3 OR 5 、CN、-C(=O)OR 4 、-OC(=O)R 4 or –NR 5 C(=O)R 4 ;
[0102] R 4 C1-C 12 a hydrocarbon group; and
[0103] R 5 is H or a C1-C6 hydrocarbon group.
[0104] In some embodiments, the cationic lipid is a compound having the structure:
[0105] In some embodiments, the cationic lipid is a compound having the structure:
[0106] In some embodiments, the neutral phospholipid (also referred to as neutral lipid in the present disclosure, the two are used interchangeably) is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), oleoylphosphatidylcholine (POPC), and 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE). In some specific embodiments, the neutral phospholipid is DSPC.
[0107] In some embodiments, the PEG-lipid is a combination of one or more selected from the group consisting of 2-[(polyethylene glycol)-2000]-N,N-tetracosylacetamide (ALC-0159), 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-disterylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglyceramide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE), PEG-1,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA), or DMG-PEG2000. In some specific embodiments, the PEG-lipid is DMG-PEG2000.
[0108] In some embodiments, the steroidal lipid is selected from the group consisting of avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprosterol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fucoxosterol, hexahydroluminosterol, hydroxycholesterol, and polypeptide-modified cholesterol; lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, cholic acid, glycocholic acid, taurocholic acid, deoxycholic acid, and lithocholic acid. In some specific embodiments, the steroidal lipid is cholesterol.
[0109] In some embodiments, the lipids include a cationic lipid such as DLin-MC3-DMA, ALC-0315, or SM-102, a PEG-lipid such as DMG-PEG2000, a neutral phospholipid such as DSPC, and optionally a steroidal lipid such as cholesterol.
[0110] In some embodiments, in the lipid nanoparticles, the cationic lipid accounts for 25-75%, the neutral phospholipid accounts for 5-20%, the PEG-lipid accounts for 1-5%, and the steroidal lipid accounts for 0-50%, by molar percentage.
[0111] In some embodiments, in the lipid nanoparticles, the molar percentage content of the cationic lipid in the lipid component is 20-60%, the molar percentage content of the neutral phospholipid in the lipid component is 5%-25%, the molar percentage content of the steroidal lipid in the lipid component is 25%-55%; and the molar percentage content of the PEG-lipid in the lipid component is 0.1%-15%.
[0112] In some embodiments, the molar ratio of cationic lipid:neutral phospholipid:PEG-lipid:steroidal lipid in the lipid nanoparticles is 30-60:1-20:0.1-10:20-50. In some embodiments, the molar ratio of cationic lipid:neutral phospholipid:PEG-lipid:steroidal lipid in the lipid nanoparticles is 40-60:10-20:1-5:30-50. In some embodiments, the molar ratio of cationic lipid:neutral phospholipid:PEG-lipid:steroidal lipid in the lipid nanoparticles is 45:10:2:43 or 40:10:2:48.
[0113] In nucleic acid-lipid nanoparticles, the nucleic acid is encapsulated in lipid nanoparticles formed by lipids. In some embodiments, the mass ratio (w / w) of nucleic acid to total lipids in the lipid nanoparticles is in the range of 1:10-30.
[0114] In some embodiments, the nucleic acid-lipid nanoparticles have an average particle size of 50-200 nm. In some embodiments, the nucleic acid-lipid nanoparticles have a net neutral charge at neutral pH. In some embodiments, the nucleic acid-lipid nanoparticles have a polydispersity of less than 0.4.
[0115] The preparation method of the nucleic acid-lipid nanoparticles disclosed herein comprises encapsulating the nucleic acid in the lipid nanoparticles. Specifically, cationic lipids, neutral phospholipids, PEG-lipids and optional steroidal lipids are dissolved in a solvent and then mixed with the nucleic acid.
[0116] In some embodiments, the preparation method of nucleic acid-lipid nanoparticles comprises dissolving cationic lipids, neutral phospholipids, PEG-lipids, and optional steroidal lipids in ethanol, and then mixing them with the diluted mRNA diluent, and then ultrafiltration, dilution, and filtration to obtain the nanoparticles; preferably, cationic lipids, neutral phospholipids, PEG-lipids, and optional steroidal lipids are dissolved in ethanol, and then mixed with the diluted mRNA diluent at a certain flow rate ratio, and then ultrafiltration, dilution, and filtration to obtain the nanoparticles; preferably, the ultrafiltration method is tangential flow filtration; more preferably, the mixing method can be turbulent mixing, laminar mixing, or microfluidic mixing.
[0117] Nucleic acid-lipid nanoparticle compositions
[0118] The present disclosure provides a nucleic acid-lipid nanoparticle composition comprising the following components: a nucleic acid, a lipid, and lactate, wherein the lactate is selected from sodium lactate or potassium lactate and is present in an amount of 5-100 mM, such as 5-75 mM, 5-50 mM, or 10-100 mM, preferably 5-50 mM. The nucleic acid, lipid, and nucleic acid-lipid nanoparticle are as defined herein.
[0119] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises a buffer, wherein the ratio of the buffer to lactate is 0.25-1:1.
[0120] In some embodiments, the buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer, and tris buffer. The content of the buffer is 1.25-100 mM, such as 2.5-100 mM, 5-100 mM, 5-75 mM, or 5-50 mM. Preferably, the content of the buffer is 1.25-50 mM, or 5-50 nM.
[0121] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises other excipients, which are a combination of one or more selected from the group consisting of sodium acetate, tromethamine, potassium dihydrogen phosphate, sodium chloride, disodium hydrogen phosphate, and sucrose.
[0122] In some embodiments, the pH of the nucleic acid-lipid nanoparticle composition is 1.0-14.0, for example, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, and a numerical range consisting of any two of the above values as endpoints and values within the numerical range, for example, 2.0-13.0, 3.0-12.0, 4.0-11.0, 5.0-10.0, 5.0-9.0, 6.0-9.0, 6.0-8.0, 6.0-7.0, 7.0-8.0. In some embodiments, the pH of the nucleic acid-lipid nanoparticle composition is 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, or a numerical range consisting of any two of the above values as endpoints and a value within the numerical range.
[0123] In some embodiments, the nucleic acid is selected from the group consisting of ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, ployI:C, SamRNA and 5'-pppRNA.
[0124] In some embodiments, the lipids include cationic lipids, neutral phospholipids, PEG-lipids, and optionally steroidal lipids.
[0125] In some embodiments, the nucleic acid is encapsulated in lipid nanoparticles (LNPs).
[0126] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises a lyoprotectant, which is further prepared as a lyophilized preparation. Non-limiting examples of lyoprotectants are selected from a combination of one or more of the group consisting of sucrose, trehalose, lactose, cyclodextrin, and mannitol.
[0127] In a non-limiting embodiment, the lyoprotectant comprises the following components: sucrose and trehalose, and the mass ratio of the sucrose to the trehalose is 5-15:5-11. In a non-limiting embodiment, the lyoprotectant comprises the following components: one or more of sucrose, trehalose, mannitol, glucose or lactose. In a non-limiting embodiment, the lyoprotectant comprises the following components: sucrose, trehalose, and one of mannitol or glucose or lactose, wherein the mass ratio of sucrose: trehalose: one of mannitol or glucose or lactose is 5-15:5-11:1-5. In a non-limiting embodiment, the lyoprotectant is dissolved in nuclease-free water according to the corresponding ratio of the components included therein for standby use.
[0128] Lyophilized preparation of nucleic acid-lipid nanoparticle composition
[0129] The present disclosure provides a lyophilized formulation of a nucleic acid-lipid nanoparticle composition. The nucleic acid-lipid nanoparticle composition is as defined herein.
[0130] In some embodiments, the nucleic acid-lipid nanoparticle composition further comprises a lyoprotectant. The lyoprotectant is as described in the present disclosure.
[0131] In some embodiments, the composition is further prepared as a lyophilized formulation.
[0132] In some embodiments, the lactate solid content is 0.5-10.0 wt%, for example, 0.5-7.5 wt%, 0.5-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%, and for example 0.5 wt%, 1.0 wt%, 1.5 wt%, 2.0 wt%, 2.5 wt%, 3.0 wt%, 3.5 wt%, 4.0 wt%, 4.5 wt%, 5.0 wt%, 5.5 wt%, 6.5 wt%, 7.0 wt%, 7.5 wt%, 8.0 wt%, 8.5 wt%, 9.0 wt%, 9.5 wt%, 10.0 wt%, or a numerical range defined by any two values within the above range as end points.
[0133] In some embodiments, the solid content of the buffer is 0.35-10 wt%, such as 0.35-7.5 wt%, 0.35-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%, and for example 0.35 wt%, 0.5 wt%, 0.75 wt%, 1.0 wt%, 1.5 wt%, 2.0 wt%, 2.5 wt%, 3.0 wt%, 3.5 wt%, 4.0 wt%, 4.5 wt%, 5.0 wt%, 5.5 wt%, 6.5 wt%, 7.0 wt%, 7.5 wt%, 8.0 wt%, 8.5 wt%, 9.0 wt%, 9.5 wt%, 10.0 wt%, or a numerical range defined by any two values within the above range as end points.
[0134] In some embodiments, the solid content of the lyoprotectant is 50-99.9 wt %, based on the total weight of the lyophilized formulation, for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, for example, a numerical range defined by any two values within the above range as end values.
[0135] Preparation method of nucleic acid-lipid nanoparticle composition
[0136] The present disclosure provides a method for preparing a nucleic acid-lipid nanoparticle composition, wherein the composition is prepared as a lyophilized preparation, and the preparation method comprises the following steps:
[0137] (1) Mixing the lactate solution with the nucleic acid-lipid nanoparticle stock solution, or
[0138] Add lactate to the nucleic acid solution before nucleic acid encapsulation, followed by lipid addition, or
[0139] During the ultrafiltration and fluid exchange phase of nucleic acid-lipid nanoparticles, a lactate-containing solution was used for ultrafiltration.
[0140] Wherein, the lactate is selected from sodium lactate or potassium lactate, and the content is 5-100mM, such as 5-75mM, 5-50mM or 10-100mM, preferably 5-50mM;
[0141] (2) adding a lyoprotectant; and
[0142] (3) freeze-drying to obtain a freeze-dried preparation of the nucleic acid-lipid nanoparticle composition.
[0143] The nucleic acids, lipids, nucleic acid-lipid nanoparticles, nucleic acid-lipid nanoparticle compositions, and lyophilized formulations are as defined herein.
[0144] In some embodiments, the lyoprotectant is selected from one or more of the group consisting of sucrose, trehalose, lactose, cyclodextrin, and mannitol.
[0145] In some embodiments, the solid content of the lyoprotectant is 50-99.9 wt %, based on the total weight of the lyophilized formulation, for example, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, for example, a numerical range with any two values within the above range as endpoints and a numerical value within the numerical range.
[0146] In some embodiments, step (1) further comprises adding a buffer, wherein the ratio of the buffer to lactate is 0.25-1:1.
[0147] In some embodiments, the buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer, and tris buffer. The content of the buffer is 1.25-100 mM, such as 2.5-100 mM, 5-100 mM, 5-75 mM, or 5-50 mM. Preferably, the content of the buffer is 1.25-50 mM, or 5-50 nM.
[0148] In some embodiments, the pH of the solution prepared in step (1) is 1.0-14.0, for example, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, and a numerical range consisting of any two of the above numerical values as endpoints and a numerical value within the numerical range, for example, 2.0-13.0, 3.0-12.0, 4.0-11.0, 5.0-10.0, 5.0-9.0, 6.0-9.0, 6.0-8.0, 6.0-7.0, 7.0-8.0. In some embodiments, the pH of the nucleic acid-lipid nanoparticle composition is 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, or a numerical range consisting of any two of the above values as endpoints and a value within the numerical range.
[0149] In some embodiments, the method for preparing the nucleic acid-lipid nanoparticle composition further comprises: after preparation, sterile filtration, and filling the filtered sample into vials for lyophilization. In some embodiments, the vials are partially stoppered with lyophilized rubber stoppers and then placed in a lyophilizer for lyophilization according to a predetermined program. In some embodiments, the filter membrane is 0.22 μm.
[0150] In some embodiments, freeze drying comprises the following steps: a pre-freezing stage, a primary drying stage, and a desorption drying stage.
[0151] The pre-freezing stage: the temperature is -80°C to -30°C, for example, -80°C, -70°C, -60°C, -50°C, -40°C, -30°C, or a numerical range with any two of the above values as endpoints and a value within the numerical range; the pre-freezing time is 1 to 6 hours, for example, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, or a numerical range with any two of the above values as endpoints and a value within the numerical range.
[0152] The primary drying stage (also known as the sublimation drying stage): the temperature is -60°C to 0°C, for example, -60°C, -50°C, -40°C, -30°C, -20°C, -10°C, 0°C, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range; the end temperature is -5°C to 0°C, for example, -5°C, -4°C, -3°C, -2°C, -1°C, 0°C, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range; the vacuum pressure is controlled to be ≤10Pa; the duration of the primary drying stage is 5 to 100 hours, for example, 5 hours, 10 hours, 20 hours, 30 hours, 40 hours, 50 hours, 60 hours, 70 hours, 80 hours, 90 hours, 100 hours, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range. In some embodiments, the primary drying stage is divided into 2 to 8 stages with a gradient temperature increase, each stage with a temperature increase of 5 to 30° C., each stage with a maintenance time of 0.5 to 10 hours, and the vacuum pressure is controlled to be ≤10 Pa.
[0153] The desorption and drying stage: the temperature is 0°C to 35°C, for example, 0°C, 5°C, 10°C, 15°C, 20°C, 25°C, 30°C, 35°C, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range, the end temperature is 30°C to 35°C, for example, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range, the vacuum pressure is controlled to be ≤10Pa, and the desorption and drying stage lasts for 2 to 15 hours, for example, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, or a numerical range with any two of the above values as endpoints and a numerical value within the numerical range.
[0154] Use and application
[0155] The present disclosure provides use of the nucleic acid-lipid nanoparticle composition of the present disclosure in preparing a medicament.
[0156] In some embodiments, the medicament is a vaccine.
[0157] In some embodiments, the vaccine is a vaccine for the prevention of cancer, a therapeutic tumor vaccine, a viral infection, a bacterial infection, or a fungal infection.
[0158] In some embodiments, the virus is selected from the group consisting of norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, poliovirus, rabies virus, and rotavirus.
[0159] In some embodiments, the drug is an oral formulation, an intramuscular injection formulation, a subcutaneous injection formulation, an intravenous injection formulation, or an inhaled formulation.
[0160] In some embodiments, the inhalation formulation is a nebulized inhaler or a dry powder inhaler.
[0161] Example
[0162] The following will clearly and completely describe the technical solutions of the present invention in conjunction with the embodiments. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.
[0163] The technical solutions and beneficial effects of the present invention are further described below in conjunction with preferred embodiments.
[0164] Example 1 Investigation of different types of lactates
[0165] Model sample:
[0166] The mRNA encoding the herpes zoster virus gE protein (gE-mRNA, about 2300 bp) was used as the model mRNA, and the mRNA lipid nanoparticles (i.e., mRNA-LNP) without sodium lactate added and freeze-dried were used as the model sample.
[0167] The preparation process is as follows: the mRNA stock solution is diluted with sodium acetate buffer to a concentration of 135 μg / ml, and a lipid mixture solution is prepared according to the molar ratio of cationic lipid ALC-0315:DSPC:cholesterol:DMG-PEG 2000 of 49:10:39.5:1.5; after encapsulation is completed on the nanomedicine manufacturing equipment, the solution is replaced by ultrafiltration, concentrated, and then sterile filtered through 0.22 μm to collect the mRNA-LNP mother solution.
[0168] To further investigate the freeze-drying effect of lactate-based mRNA-LNPs, in addition to sodium lactate, different lactate mother solutions were added to mRNA-LNPs, and the freeze-drying effects of potassium lactate, ammonium lactate, lactic acid, lithium lactate, magnesium lactate, and calcium lactate were investigated and compared. In Examples 1-1 to 1-7, the amount of different types of lactate used was 20 mM. Example 1-8 is an mRNA-protamine complex with sodium lactate added (to prepare the mRNA-protamine complex, mRNA was prepared into a 0.4 g / L aqueous solution, mixed with protamine at a ratio of mRNA / protamine (4:1 w / w), and then sodium lactate mother solution and lyoprotectant mother solution were added and diluted to an mRNA concentration of about 100 μg / mL, a sodium lactate concentration of 20 mM, and a lyoprotectant of at least 5% (w / v). The lyoprotectant was selected from one or more of sucrose, trehalose, mannitol, glucose, maltose, and lactose. The mRNA-LNP and mRNA-protamine complexes were lyophilized and evaluated separately.
[0169] A lyoprotectant stock solution was added to the mRNA-LNP stock solution. After sample preparation, the sample was sterile-filtered at 0.22 μm and filled into 2R vials at a volume of 0.6 mL / vial. After half-stoppering with a lyophilization stopper, the sample was placed in a lyophilizer (SP Scientific VirTis Genesis 25L Pilot Lyophilizer) and lyophilized according to the pre-set program (prefreeze at -55°C for 3 hours, heat to -20°C for 50 minutes, perform primary drying for 10 hours, then heat to 30°C at the maximum heating rate for desorption drying for 10 hours, and maintain a pressure of 50 mTorr for both the primary and secondary drying stages).
[0170] Table 1 Freeze-drying effects of different lactates
[0171] The free mRNA was fluorescently detected by combining RiboGreen RNA reagent with the free mRNA, and the amount of free mRNA was determined using a fluorescence analyzer. At the same time, the membrane was permeabilized with Triton X-100 to determine the total amount of mRNA.
[0172] Encapsulation efficiency (EE%) = (total mRNA amount - free mRNA amount) / total mRNA amount * 100%
[0173] mRNA integrity assay: The mRNA-LNP sample was diluted and denatured at 70°C. Dye-Gel was prepared and injected into a gel press. Next, the mRNA marker, ladder, and sample were added. The mRNA integrity profile of the sample was efficiently determined using gel electrophoresis using an Agilent 5200 Bioanalyzer System.
[0174] As can be seen from Table 1, the results of Examples 1-1 to 1-7 show that both potassium lactate and sodium lactate have good freeze-drying effects. However, considering that in certain special dosage forms, such as the mainstream dosage form of mRNA-LNP is an injection, a higher potassium ion concentration will affect the electrophysiology of myocardial cells after injection, and there is a certain safety risk probability. Therefore, in the case where both potassium lactate and sodium lactate can achieve good freeze-drying effects, sodium lactate can be preferred. At the same time, the results of Example 1-8 show that sodium lactate is used for protamine-mRNA complexes, and it completely collapses after freeze-drying, and the encapsulation efficiency and integrity are both low.
[0175] The prior art holds that the introduction of salts will be detrimental to the freeze-drying of lipid nanoformulations. The present invention breaks through the limitations of traditional research and chooses to add lactate. To further demonstrate the properties of lactate in freeze-drying, electron microscopy observation was performed on sample No. 1 in Example 1-1.
[0176] Take the graphene grid, place it face up in a watch glass, and glow in a glow meter for 2 seconds (manually stop after the time is up); perform frozen sample preparation: 1) open the frozen sample preparation machine half an hour in advance, replace the filter paper, add double distilled water to the frozen sample preparation machine, and enter the frozen sample preparation parameters of Blot Time (2.5s), Blot Force (3s), Wait Time (3s), and Blot Total (1s) to prepare the sample.
[0177] Prepare liquid nitrogen and liquid ethane in the mold; clamp the grid onto the fixture in the slot orientation, then install the fixture and grid into the freezing sample preparation machine. Pipette 3 μl of the reconstituted Example 1-1 sample and carefully pipette it onto the grid surface (taking care to avoid puncturing the grid with the pipette tip). Run the instrument, which will operate according to sample preparation conditions. Remove the fixture, quickly transfer the grid from the ethane to the liquid nitrogen (avoiding bending the grid), and install the grid in the electron microscope inspection wheel mold. Store the sample securely, and the freezing is complete.
[0178] The frozen grid was cooled and loaded onto a machine (FEI 200KV Talos Arctica G2 field emission transmission electron microscope) for electron microscopy observation and photography.
[0179] From the cryo-electron microscopy results of sample No. 1 in Example 1-1, it can be seen that even if 20 mM sodium lactate with a higher salt concentration is used for freeze-drying, the preparation after freeze-drying and reconstitution still presents a uniform spherical shape, and the addition of sodium lactate for freeze-drying does not significantly change the microscopic morphology of mRNA-LNP (Figure 1).
[0180] Example 2 Sodium lactate alone and in combination
[0181] Table 2 Lyophilization buffer composition
[0182] According to the preparation method of the model sample in Example 1, an mRNA-LNP mother solution with an mRNA concentration of about 200 μg / mL was prepared. The mRNA-LNP mother solution did not contain buffer. An appropriate volume of mRNA-LNP mother solution was added to an appropriate volume of 100mM pH7.5 Tris mother solution, pH8.0 Tris mother solution, pH7.5 sodium lactate mother solution, and then an appropriate volume of ultrapure water and lyophilization protectant mother solution was added to dilute the mRNA concentration to about 100 μg / mL. The final buffer composition corresponds to Table 2. After the sample preparation of sequence numbers 1-3 was completed, 0.22 μm sterile filtration was performed, and the filtered sample was filled into a 2R cillin bottle at a volume of 0.6 mL / bottle. After the freeze-drying stopper was half-stoppered, it was placed in a freeze dryer and freeze-dried according to a predetermined program.
[0183] After lyophilization, the container was filled with nitrogen, the stopper was removed from the container, and the cap was rolled. 0.54 mL of enzyme-free water was added to the lyophilized sample for reconstitution, and the reconstitution time was recorded. An appropriate amount of the reconstituted sample was diluted 50-fold and tested on a Malvern particle size analyzer for particle size and polydispersity coefficient. Three replicates were run and the average was taken. The reconstituted sample was also tested for pH, mRNA content, encapsulation efficiency, and integrity. The results are shown in Table 3.
[0184] Table 3 Test results of samples with different freeze-dried buffer compositions
[0185] The integrity determination patterns of samples 1-3 in Example 2 are shown in FIG2 .
[0186] 100 μL of freeze-dried and reconstituted mRNA-LNP sample was taken and added to a 0.6 mL centrifuge tube for pH measurement. The pH meter was a Mettler-Toledo FE28 model, and a micro pH probe was used for measurement.
[0187] From the above experimental results, it can be seen that the freeze-dried preparation can be quickly reconstituted. The particle size of the reconstituted mRNA-LNP preparation is still within a reasonable range, the PDI is small and the particle size distribution is concentrated, the mRNA encapsulation rate and integrity are at a high level, and all samples are successfully freeze-dried.
[0188] In order to distinguish the stability differences of samples 1-3 in Example 2 in a short period of time, the lyophilized preparations of samples 1-3 were placed at 42°C for one month. Samples were taken at the first, second, third, and fourth weeks, and then reconstituted and tested for particle size, polydispersity coefficient, pH, mRNA content, encapsulation efficiency, and integrity. The results are shown in Table 4.
[0189] Table 4 Detection results of factors affecting high temperature at different time points at 42℃
[0190] Table 4 shows that after storage at 42°C, the particle size of samples 1-3 increased to a certain extent, the encapsulation efficiency decreased slightly, the mRNA content remained stable, and the integrity showed significant differentiation. As shown in Figure 3, after one month at 42°C, the integrity of the 5mM Tris group and the 20mM Tris + 5mM sodium lactate group decreased to approximately 30%, a trend similar to that reported by Muramatsu et al. However, surprisingly, the integrity of the 20mM sodium lactate group remained as high as 71.7%, significantly higher than the other two groups, even after one month at 42°C. This demonstrates that the use of 20mM sodium lactate can significantly improve the integrity of lyophilized preparations.
[0191] The experimental process showed that Example 2-2 demonstrated that the addition of sodium lactate to the nucleic acid-lipid nanoparticle formulation achieved the technical effect of improving the integrity and long-term storage stability of the nucleic acid-lipid nanoparticle lyophilized formulation. However, the pH was only 7.31, with large fluctuations during pH testing and lower than the target pH of 7.5. This is related to the weak buffering capacity of sodium lactate between pH 7 and 8. Therefore, to achieve better technical results, further attempts were made to add a small amount of Tris in combination with different amounts of sodium lactate to improve the pH buffering capacity of the formulation, thereby protecting mRNA from degradation by pH fluctuations and improving the integrity and stability of the lyophilized formulation.
[0192] Table 5 Tris and sodium lactate compound prescription settings
[0193] Following the preparation method for the model sample, an mRNA-LNP stock solution with an mRNA concentration of approximately 200 μg / mL was prepared. The buffer in the mRNA-LNP stock solution was 5 mM Tris. An appropriate volume of the mRNA-LNP stock solution was added to an appropriate volume of 100 mM sodium lactate stock solution, followed by an appropriate volume of 5 mM Tris solution and a lyoprotectant stock solution to dilute the mRNA concentration to approximately 100 μg / mL. The final buffer composition corresponded to Table 5. After the samples of sequence numbers 4-6 were prepared, they were sterile filtered at 0.22 μm. The filtered samples were filled into 2R vials at a volume of 0.6 mL / vial. After the freeze-drying rubber stoppers were partially added, the vials were placed in a freeze dryer and freeze-dried according to the predetermined program.
[0194] After lyophilization, the container was filled with nitrogen, the stopper was removed from the container, and the cap was rolled. 0.54 mL of enzyme-free water was added to the lyophilized sample for reconstitution, and the reconstitution time was recorded. An appropriate amount of the reconstituted sample was diluted 50-fold and tested on a Malvern particle size analyzer for particle size and polydispersity coefficient. Three replicates were run and the average was taken. The reconstituted sample was also tested for mRNA content, encapsulation efficiency, and integrity. The results are shown in Table 6.
[0195] Table 6 Key quality indicators and reconstitution time after freeze-drying
[0196] 100 μL of the freeze-dried and reconstituted mRNA-LNP sample and the sample before freeze-drying were respectively taken and added to a 0.6 mL centrifuge tube for pH measurement. The pH meter was a Mettler-Toledo FE28 model, and a micro pH probe was used for measurement.
[0197] The free mRNA was fluorescently detected by combining RiboGreen RNA reagent with the free mRNA, and the amount of free mRNA was determined using a fluorescence analyzer. At the same time, the membrane was permeabilized with Triton X-100 to determine the total amount of mRNA.
[0198] Encapsulation efficiency (EE%) = (total mRNA amount - free mRNA amount) / total mRNA amount * 100%
[0199] mRNA integrity assay: The mRNA-LNP sample was diluted and denatured at 70°C. Dye-Gel was prepared and injected into a gel press. Next, the mRNA marker, ladder, and sample were added. The mRNA integrity profiles of the samples were efficiently determined using gel electrophoresis using an Agilent 5200 Bioanalyzer System. The integrity assay profiles for Examples 2-4, 2-5, and 2-6 are shown in Figure 4.
[0200] The above experimental results show that the freeze-dried preparations after the combination of Tris and sodium lactate can be quickly reconstituted. The particle size of the reconstituted mRNA-LNP preparations remains within a reasonable range, with a small PDI and a concentrated particle size distribution. The mRNA encapsulation efficiency and integrity are at a high level, and all samples are successfully freeze-dried. Judging from the pH before and after freeze-drying, the introduction of Tris and sodium lactate makes the pH of the mRNA-LNP samples relatively stable before and after freeze-drying, very close to the set pH level of 7.5. The stable pH can protect the mRNA from degradation caused by pH fluctuations.
[0201] Cell expression Western-blot
[0202] HEK293 cells were used as the model cells for in vitro protein expression. 6 Cells were plated in a 6-well plate at a cell density of 100 μL / mL and cultured for 24 hours. Then, the samples of Examples 2-1 to 2-6 were reconstituted with nuclease-free water, and the model samples were added to the wells in sequence. The amount added was 20 μL, and the cells were transfected for 4 hours after mixing. The medium (containing serum) was then changed.
[0203] After 24 hours of incubation in an incubator, cells were digested with PBS and transferred to a centrifuge tube and centrifuged (2500 rpm for 5 minutes). The cells were collected, mixed with 1 mL of PBS, and transferred to a 1.5 mL EP tube. After centrifugation, the lower layer of cells was removed. 200 μL of protein lysis buffer (1 μL of protease inhibitor per 100 μL of CHAPS) was added to each sample and lysed on ice for 1 hour. After centrifugation at 4°C (13500 rpm for 20 minutes), the supernatant was removed and the sample was subjected to a western-blot experiment to determine protein expression.
[0204] First, check the electrophoresis device for leaks (fill it with water. If the liquid level does not drop within 5 minutes, it means the device can be used). After the leak test is completed, clean the water. Add the prepared 12% separation gel (volume fraction) to the electrophoresis device, and then add anhydrous ethanol (to suppress bubbles). After it is allowed to stand for 30 minutes, after the separation gel solidifies, pour out the anhydrous ethanol and use filter paper to absorb the excess liquid. Add concentrated gel and quickly insert the comb. After it is allowed to stand for 30 minutes, the concentrated gel solidifies. Place the device in the electrophoresis tank and add electrophoresis solution (1 × SDS-PAGE buffer) was used to cover the platinum wire, the comb was pulled out, and the protein expression samples of samples 1-3 in Example 1, samples 4-6 in Example 3, and the model sample were added in sequence; electrophoresis was performed (100 V, 300 mA), and the positions of bromophenol blue and marker were observed during the electrophoresis process, and the gel was stopped when they reached the bottom of the gel; the gel after electrophoresis was taken out and separated according to the dividing line between the stacking gel and the separating gel, the stacking gel was removed, the separating gel was retained, and the separating gel and the filter paper were placed on 1× blotting The PVDF membrane was soaked in anhydrous methanol to activate it; 3 layers of filter paper, 1 layer of PVDF membrane, separation gel, and 3 layers of filter paper were placed on the transfer instrument in this order and bubbles were driven out. The power was turned on, 15V (5V to 15V gradient increase), 300mA, and the transfer was performed for 1 hour and 40 minutes; the PVDF membrane (with protein transferred) was immersed in 1×PBST containing 5% skim milk powder and blocked at room temperature for 2 hours. After 2 hours, the excess skim milk powder was washed off with 1×PBST; the membrane was placed in a 15mL centrifuge tube containing the primary antibody (diluted with 5% skim milk powder according to the instructions) and incubated overnight at 4°C. The excess primary antibody was washed off with 1×PBST; the PVDF membrane that had been blocked with the primary antibody was placed in a 15mL centrifuge tube containing the secondary antibody (diluted with 5% skim milk powder according to the instructions) and incubated at room temperature for 1 hour (be careful to avoid light). After washing off the excess secondary antibody, it was detected and analyzed using the Odyssey infrared laser imaging system.
[0205] The experimental results are shown in Figure 5. It can be seen that there was no significant difference in the expression of gE protein among the samples of Example 2-1 to Example 2-6 in Example 2, and the expression level was even higher than that of the unlyophilized model sample. There was no significant difference in the cell transfection efficiency among the sample groups, indicating that the freeze-drying process did not reduce the cellular bioactivity of the mRNA-LNP. Furthermore, sodium lactate alone or in combination with Tris at different dosages did not significantly affect the cellular bioactivity of the mRNA-LNP.
[0206] In vivo immunization of mice
[0207] BALB / c mice were taken, and 9 groups of preparations, including three groups of preparations in Examples 2-1 to 2-3, three groups of preparations after four weeks of high temperature acceleration at 42°C in Examples 2-1 to 2-3, and three groups of preparations in Examples 2-4 to 2-6, were reconstituted and compared with non-lyophilized model samples. The mice were randomly divided into 10 groups and injected intramuscularly with 100 uL (5 μg) on days 0 and 14. Blood samples were collected on days 14 and 28 for IgG detection and alternative neutralizing antibody detection against VZV gE protein; spleen cells were collected for gE protein antigen-specific ICS detection; PBMC cells were collected in a combined tube for gE protein antigen-specific ELISPOT detection.
[0208] As shown in Figures 6 and 7, the levels of humoral and cellular immunity after freeze-drying were close to those of the model samples before freeze-drying. Freeze-drying did not significantly reduce the immune levels of the mice. Some freeze-dried preparations even showed significantly better immune activity than the model preparations before freeze-drying. In addition, it was found that after the freeze-dried preparations were stored at 42°C for 4 weeks, the immune activity of mice with different formulations showed significant differentiation. The immune activity of mice containing sodium lactate after storage at 42°C for 4 weeks did not show a significant decrease compared to the freeze-drying zero point. The immune activity of mice with the other two groups of freeze-dried samples stored at 42°C for 4 weeks showed a significant decrease, which corresponds to the integrity level after storage at 42°C for 4 weeks.
[0209] Table 7 Mouse immune sample information
[0210] Example 3 Sodium lactate dosage investigation experiment
[0211] To investigate the effect of different sodium lactate dosages on the freeze-drying of LNP preparations, LNP preparations with different sodium lactate concentrations were prepared and freeze-dried according to the preparation method and freeze-drying procedure in Example 1. The specific freeze-drying results are shown in Table 8.
[0212] Table 8 Investigation of different sodium lactate dosages 1Comparative Example 3-1 was used as a control without the addition of sodium lactate, and 20mM pH7.5 Tris buffer (Moderna's marketed new crown vaccine mRNA-1273 buffer formula) was added for freeze-drying. 2 Theoretical calculations were performed based on the complete removal of water after freeze-drying. The solid matter after freeze-drying consisted of lyoprotectant, mRNA-LNP, and sodium lactate. The theoretical mass fraction (%) of sodium lactate in the solid after freeze-drying was the ratio of the theoretical mass of sodium lactate after freeze-drying to the sum of the masses of lyoprotectant, mRNA-LNP, and sodium lactate.
[0213] From the freeze-drying results of Examples 3-1 to 10, it can be seen that when the amount of sodium lactate is 100mM or more, the appearance of the freeze-dried powder cake has certain defects, especially when the amount is 125mM or more, it collapses completely. As for the encapsulation efficiency of the freeze-dried preparation, when the amount of sodium lactate is above 50mM, the encapsulation efficiency after freeze-drying decreases significantly with the increase of the amount of sodium lactate, especially when the amount of sodium lactate is 100mM or more, the encapsulation efficiency after freeze-drying is less than 80%. From the perspective of integrity, due to the certain errors in the detection method itself, it can be considered that when the amount of sodium lactate is 5-75mM, the integrity of the freeze-dried preparation is at a high level and does not decrease significantly, while when the amount of sodium lactate reaches a concentration of 100mM or more, the integrity after freeze-drying decreases significantly, which corresponds to the decrease in the encapsulation efficiency after freeze-drying. It was also noted that there was a certain gap between the pH after freeze-drying and reconstitution and the pH 7.5 set before freeze-drying. In particular, when the dosage of sodium lactate was 75 mM or above, the pH after freeze-drying and reconstitution dropped to about 7. This was related to the weak buffering capacity of sodium lactate itself and the near-neutral nature of the solution.
[0214] Based on the preparation of freeze-dried preparations containing different amounts of sodium lactate, in order to further confirm the thermal stability of freeze-dried preparations with different amounts of sodium lactate, an experiment on the influencing factors of high temperature at 42°C was further conducted. The integrity of samples placed at 42°C for two weeks and four weeks was tested. The specific experimental results are shown in Table 9. After being placed at 42°C for four weeks, the integrity of the samples of Comparative Example 3-1 and Example 3-1 was reduced to about 30%, while the integrity of the remaining samples after being placed at 42°C for four weeks was still between 73-83% and was relatively close to the results of Example 2-2.
[0215] Combined with the integrity results of the samples in Example 2-2 / 2-3 after being placed at 42°C for four weeks, it is reflected that when the sodium lactate dosage is 5 mM, the effect of protecting mRNA when placed at a high temperature of 42°C is limited. The degree of integrity reduction of the lyophilized preparation using only 5 mM sodium lactate after being placed at 42°C for four weeks is basically the same as that of the preparation without sodium lactate, and is much lower than that of the preparation with 10 mM or more sodium lactate. This may be related to the mechanism by which sodium lactate protects mRNA from degradation under high temperature conditions. Sodium lactate protects mRNA by reducing the activity of a small amount of residual water in the lyophilized preparation. When the sodium lactate dosage is low, it may not be possible to completely reduce the activity of the residual water in the lyophilized preparation.
[0216] Table 9 Experimental investigation on factors affecting high temperature at 42℃ with different sodium lactate dosage
[0217] These experiments show that when the sodium lactate dosage is 5-100mM, the mRNA-LNP preparations can be freeze-dried to an acceptable level; when the sodium lactate dosage is in the range of 5-75mM, a freeze-dried preparation with the best integrity after freeze-drying can be obtained; when the sodium lactate dosage is 5-50mM, a freeze-dried preparation with excellent key quality indicators after freeze-drying can be obtained; when the sodium lactate dosage is in the range of 10-100mM, the freeze-dried preparation has excellent thermal stability. In summary, most preferably, when the sodium lactate concentration is in the range of 10-50mM, a freeze-dried preparation with excellent key quality indicators after freeze-drying and excellent high-temperature thermal stability can be obtained.
[0218] Example 4 Investigation of the dosage of different types of buffer and sodium lactate
[0219] In the experiments of Examples 2 and 3, it was found that when sodium lactate was used alone, due to its weak buffering capacity, the pH was prone to large fluctuations, which could potentially affect the technical effect of sodium lactate in increasing the stability of the mRNA formulation during the lyophilization process. To achieve better technical results, a target amount of sodium lactate and various buffer solution stock solutions were added to the mRNA-LNP mother solution. Further investigation was conducted on the lyophilization of sodium lactate after compounding with buffer solutions of varying concentrations and types. The specific implementation method was the same as in Example 1. The specific investigation details are shown in Table 10.
[0220] From the results of the investigation in Table 11, it can be seen that after adding the buffer pair and re-freezing and re-dissolving with sodium lactate, the measured pH value is very close to the target pH. Comparing Example 2 and Example 3, the addition of the buffer pair can significantly stabilize the pH of the formulation after re-freezing. When the amount of sodium lactate is 20mM, it is re-freeze-dried with different amounts of acetic acid, phosphoric acid, Tris, citric acid, and histidine buffer pairs. When the amount of the buffer pair is 30mM and 50mM (i.e., the molar ratio of buffer salt to sodium lactate is 1.5 and 2.5), the encapsulation efficiency after lyophilization is significantly lower and the corresponding integrity is also lower (encapsulation efficiency is less than 80% or integrity is less than 85%), which reflects that the high molar ratio of buffer salt to sodium lactate is not conducive to the freeze-drying of mRNA-LNP. When the molar ratio of acetic acid, phosphoric acid, Tris, citric acid, and histidine buffer to sodium lactate is within the range of 0.25-1, they can be compounded with lactic acid to obtain better freeze-drying. Preferably, the molar ratio of acetic acid, phosphoric acid, Tris, citric acid, and histidine buffer to sodium lactate is within the range of 0.25-1 for compounding and freeze-drying.
[0221] Table 10 Investigation of the dosage of different types of buffer and sodium lactate 1 Theoretical calculations were performed based on the complete removal of water after freeze-drying. The solid matter after freeze-drying consisted of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. The theoretical mass fraction (%) of buffer salt in the solid after freeze-drying was the ratio of the theoretical mass of buffer salt after freeze-drying to the sum of the masses of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. 2 Theoretical calculations were performed based on the complete removal of water after freeze-drying. The solid matter after freeze-drying consisted of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. The theoretical mass fraction (%) of sodium lactate in the solid after freeze-drying was the ratio of the theoretical mass of sodium lactate after freeze-drying to the sum of the masses of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. 3 The molar concentration of the buffer salt in the freeze-dried preparation is divided by the molar concentration of sodium lactate.
[0222] Table 11 Results of investigation on the dosage of different types of buffer and sodium lactate
[0223] In the experimental results of the compounding investigation of sodium lactate with a dosage of 20 mM and different buffer salts of 5-50 mM in Table 11, it was confirmed that the molar ratio of buffer salt to sodium lactate was better in the range of 0.25-1. In order to further verify the feasibility of compounding and freeze-drying with a molar ratio of buffer salt to sodium lactate in the range of 0.25-1, the freeze-drying effect of sodium lactate with different molar ratios of buffer salts when the concentrations were 30 / 40 / 50 mM respectively was further investigated. The specific investigation content is shown in Table 12.
[0224] Sodium lactate concentrations of 30 / 40 / 50 mM were mixed with Tris buffer or histidine buffer at different molar ratios and freeze-dried. The specific results are shown in Table 13. When the molar ratio of buffer salt to sodium lactate was 0.2, the pH value after freeze-drying and reconstitution deviated from the target pH 7.5. When the molar ratio of buffer salt to sodium lactate was 0.25 or above, the pH value after freeze-drying and reconstitution was very close to the target pH 7.5. This reflects that when the molar ratio of buffer salt to sodium lactate is too low, it cannot play an effective buffering role to stabilize the pH of the preparation. When the molar ratio of buffer salt to sodium lactate was 1.5, even though the amount of sodium lactate was different at 30 / 40 / 50 mM, the encapsulation rate and integrity after freeze-drying and reconstitution were low. This may be because the excessive amount of buffer salt affected the freeze-drying effect. When the molar ratio of buffer salt to sodium lactate was 0.25-1, the freeze-drying effect was similar to that in Table 11, and the quality indicators of the preparation before and after freeze-drying were close to those before freeze-drying.
[0225] In summary, when different amounts of sodium lactate are used and mixed with different buffers for freeze-drying, the pH stability and freeze-drying effect are better when the molar ratio of buffer salt to sodium lactate is maintained between 0.25-1. The preferred molar ratio of buffer salt to sodium lactate is 0.25-1 for freeze-drying.
[0226] Table 12 Investigation of compounding of different types of buffer with different amounts of sodium lactate 1 Theoretical calculations were performed based on the complete removal of water after freeze-drying. The solid matter after freeze-drying consisted of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. The theoretical mass fraction (%) of buffer salt in the solid after freeze-drying was the ratio of the theoretical mass of buffer salt after freeze-drying to the sum of the masses of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. 2 Theoretical calculations were performed based on the complete removal of water after freeze-drying. The solid matter after freeze-drying consisted of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. The theoretical mass fraction (%) of sodium lactate in the solid after freeze-drying was the ratio of the theoretical mass of sodium lactate after freeze-drying to the sum of the masses of lyoprotectant, mRNA-LNP, sodium lactate, and buffer pair. 3 The molar concentration of the buffer salt in the freeze-dried preparation is divided by the molar concentration of sodium lactate.
[0227] Table 13 Results of compounding of different types of buffer with different amounts of sodium lactate
[0228] Example 5 Investigation of freeze-drying effects at different pH values
[0229] Based on Examples 1-4, the optimal pH range of the lyophilized preparation containing sodium lactate before lyophilization was further investigated. On the basis of a sodium lactate dosage of 20 mM, the lyophilization effects of sodium lactate alone and in combination with different types and pH buffer pairs at a concentration of 10 mM were investigated. After the different buffer pairs were compounded with sodium lactate, a suitable pH adjuster was added to adjust to the target pH. The specific lyophilization results are shown in Table 14.
[0230] Table 14 Freeze-drying effect at the same pH value
[0231] As can be seen from Table 14, at pH 6.5, the particle size growth of sodium lactate after freeze-drying after compounding with different buffer pairs is significantly greater than that at other pH values, and the particle size after freeze-drying and reconstitution is greater than 110 nm. At the same time, the encapsulation efficiency after freeze-drying and reconstitution is lower than that at other pH values; at pH 8.5, the integrity after freeze-drying is significantly reduced compared with that before freeze-drying; between pH 7.0-8.0, sodium lactate can be compounded with different buffer pairs to obtain better freeze-drying, and the quality indicators after freeze-drying are close to those before freeze-drying. When 20 mM sodium lactate is used alone for freeze-drying, good freeze-drying can also be obtained at pH 7.27 (between 7 and 8).
[0232] In summary, when the lactate-containing mRNA-LNP sample is freeze-dried, whether sodium lactate is used alone or in combination with different buffer pairs, better freeze-drying can be achieved within the pH range of 7-8, and the preferred freeze-drying pH range is 7-8.
[0233] Example 6 Freeze-drying Effects of Different Types of mRNA
[0234] Based on the investigation of traditional linear mRNA, we further confirmed whether the freeze-drying conditions that are feasible for traditional linear mRNA are applicable to self-replicating mRNA (samRNA) and circular mRNA (circRNA). Taking eGFP samRNA and circRNA as examples, eGFP samRNA and circRNA were encapsulated respectively according to the same encapsulation method as the above embodiment. After encapsulation, the replacement buffer was 50mM sodium lactate & 10mM PB buffer containing a lyoprotectant. After filling into 2R vials at a rate of 0.6mL per bottle, freeze-drying was carried out according to the freeze-drying procedure of Example 1. The freeze-drying results are shown in Table 15.
[0235] The samples in Table 15 were freeze-dried and reconstituted with enzyme-free water, and then samples were taken for cell expression experiments. 5Hep3B cells were seeded into 6-well culture plates at a density of 1 mL / well at 400 cells / mL. After 24 hours, each well was transfected with 2.5 μg of mRNA-LNPs. The plates were then incubated at 37°C in a 5% CO2 incubator. A negative control group was transfected with an equal volume of saline. After 24 hours, microscopic imaging was performed, as shown in Figure 8.
[0236] Table 15 Lyophilization results of different types of mRNA
[0237] As shown in Table 15, all three types of mRNA molecules were successfully encapsulated and lyophilized, with multiple post-lyophilization parameters closely matching those before and after lyophilization. Figure 8 also shows that cellular expression levels for the three mRNA types were very similar before and after lyophilization, indicating that lyophilization did not reduce the bioactivity of the three mRNA formulations. This demonstrates that the lyophilization formulation and process are highly compatible with different nucleic acid types, enabling successful lyophilization of all nucleic acid types.
[0238] Samples 6-1 and 6-2 of Examples involve SamRNA and circRNA. To further demonstrate the freeze-drying properties of the lactate of the present invention, samples 6-1 and 6-2 of Examples were observed under an electron microscope.
[0239] Take the graphene grid, place it face up in a watch glass, and glow in a glow meter for 2 seconds (manually stop after the time is up); perform frozen sample preparation: 1) open the frozen sample preparation machine half an hour in advance, replace the filter paper, add double distilled water to the frozen sample preparation machine, and enter the frozen sample preparation parameters of Blot Time (2.5s), Blot Force (3s), Wait Time (3s), and Blot Total (1s) to prepare the sample.
[0240] Prepare liquid nitrogen and liquid ethane in the mold; clamp the grid onto the fixture in the slot orientation, then install the fixture and grid together on the freezing sample preparation machine; pipette 3 μl of the reconstituted sample from Example 6-1 or Example 6-2 and carefully pipette it onto the surface of the grid (taking care to avoid puncturing the grid with the pipette tip). Run the instrument, which will operate according to sample preparation conditions; remove the fixture, quickly transfer the grid from the ethane to the liquid nitrogen (avoiding bending the grid), and install the grid in the electron microscope inspection wheel mold. Store the sample, and the freezing is complete.
[0241] The frozen grid was cooled and loaded onto a machine (FEI 200KV Talos Arctica G2 field emission transmission electron microscope) for electron microscopy observation and photography.
[0242] From the electron microscopy images of the sample in Example 6-1 ( FIG. 9 ) and the sample in Example 6-2 ( FIG. 10 ), it can be seen that even under the relatively high salt concentration conditions of 50 mM sodium lactate & 10 mM PB buffer, the LNPs encapsulating samRNA and circRNA still present a uniform spherical shape after freeze-drying and reconstitution, and freeze-drying does not cause the microscopic morphology of the preparation to be destroyed.
[0243] Example 7 Lyophilization study of different lipid nanoparticles
[0244] Using eGFP mRNA as an example, LNP-mRNA encapsulation with different cationic lipids was performed. Three cationic lipids were dissolved in ethanol according to the molar ratios listed in Table 16, and mRNA was dissolved in pH 4.0 acetate buffer. The mRNA-LNP compositions were prepared using the Precision Nanosystems Ignite microfluidic system at a lipid mixture:mRNA flow rate ratio of 1:3 (see Table 16 for the specific formulation). The encapsulated mRNA-LNPs were transferred to the corresponding buffer listed in Table 16, and sodium lactate stock solution was added to the target concentration. A lyoprotectant stock solution was then added to achieve the same lyoprotectant composition as in Example 1. After sterile filtration, the mRNA was filled into 2R vials at a rate of 0.6 mL per vial and lyophilized. Samples were collected before and after lyophilization to test encapsulation efficiency, average particle size, PDI, and integrity, and samples were also collected for cell expression experiments.
[0245] Table 17 shows the various parameters of LNP encapsulation before and after lyophilization. The three different lipid nanoparticles were able to effectively encapsulate mRNA under different nitrogen-phosphorus ratios, resulting in LNPs with excellent performance. Lyophilization was performed using different sodium lactate dosages and in combination with different buffers. The physicochemical parameters after lyophilization were very close to those before lyophilization, indicating that all samples were well lyophilized. Cell expression results before and after lyophilization are shown in Figure 11. All three LNP formulations showed high cellular expression after lyophilization, even improving compared to their pre-lyophilization levels.
[0246] Table 16 Prescription information of different three-component LNPs
[0247] Table 17 Lyophilization results of different three-component LNPs
[0248] Take the graphene grid, place it face up in a watch glass, and glow in a glow meter for 2 seconds (manually stop after the time is up); perform frozen sample preparation: 1) open the frozen sample preparation machine half an hour in advance, replace the filter paper, add double distilled water to the frozen sample preparation machine, and enter the frozen sample preparation parameters of Blot Time (2.5s), Blot Force (3s), Wait Time (3s), and Blot Total (1s) to prepare the sample.
[0249] Prepare liquid nitrogen and liquid ethane in the mold; clamp the grid onto the fixture in the slot orientation, then install the fixture and grid together on the freezing sample preparation machine; pipette 3 μl of the reconstituted samples of Example 7-1, Example 7-2, and Example 7-3 and carefully pipette onto the surface of the grid (taking care to avoid puncturing the grid with the tip of the pipette); operate the instrument, which will operate according to sample preparation conditions; remove the fixture, quickly transfer the grid from the ethane to the liquid nitrogen (avoiding bending the grid), and install the grid in the electron microscope inspection wheel mold. Store the samples, and the freezing process is complete.
[0250] The frozen grid was cooled and loaded onto a machine (FEI 200KV Talos Arctica G2 field emission transmission electron microscope) for electron microscopy observation and photography.
[0251] From the electron microscope images of the sample of Example 7-1 ( FIG. 12 ), the sample of Example 7-2 ( FIG. 13 ), and the sample of Example 7-3 ( FIG. 14 ), it can be seen that the three LNPs have good microscopic morphologies after freeze-drying.
[0252] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A nucleic acid-lipid nanoparticle composition comprising the following components: nucleic acid, lipid and lactate, wherein the lactate is selected from sodium lactate or potassium lactate, and the content is 5-100mM, such as 5-75mM, 5-50mM or 10-100mM, preferably 5-50mM.
2. The nucleic acid-lipid nanoparticle composition according to claim 1, further comprising a buffer, wherein the content ratio of the buffer to lactate is 0.25-1:
1.
3. The nucleic acid-lipid nanoparticle composition according to claim 2, in, The buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer and tris buffer. Preferably, the buffer content is 1.25-50 mM.
4. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 3, further comprising a lyoprotectant, preferably a combination of one or more selected from the group consisting of sucrose, trehalose, lactose, cyclodextrin and mannitol.
5. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 4, in, The pH of the nucleic acid-lipid nanoparticle composition is 1.0-14.0, such as 2.0-13.0, preferably 5.0-9.0, and more preferably 7.0-8.
0.
6. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 5, in, The nucleic acid is selected from the group consisting of ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, ployI:C, SamRNA and 5'-pppRNA.
7. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 6, in, The nucleic acid is encapsulated in lipid nanoparticles (LNP).
8. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 7, in, The lipids include cationic lipids, neutral phospholipids, PEG-lipids and optionally steroidal lipids.
9. The nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 8, in, The composition is prepared as a lyophilized preparation.
10. The nucleic acid-lipid nanoparticle composition according to claim 9, in, Based on the total weight of the lyophilized preparation, the lactate solid content is 0.5-10.0 wt%, such as 0.5-7.5 wt%, 0.5-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%.
11. The nucleic acid-lipid nanoparticle composition according to claim 9 or 10, in, Based on the total weight of the lyophilized preparation, the solid content of the buffer is 0.35-10.0 wt%, such as 0.35-7.5 wt%, 0.35-5.0 wt% or 1.0-10 wt%, preferably 0.5-5.0 wt%.
12. A method for preparing a nucleic acid-lipid nanoparticle composition, in, The composition is prepared as a lyophilized preparation, and the preparation method comprises the following steps: (1) mixing the lactate solution with the nucleic acid-lipid nanoparticle stock solution, or Add lactate to the nucleic acid solution prior to nucleic acid encapsulation, followed by lipid addition, or During the ultrafiltration of nucleic acid-lipid nanoparticles, a lactate-containing solution was used for ultrafiltration. Wherein, the lactate is selected from sodium lactate or potassium lactate, and the content is 5-100mM, such as 5-75mM, 5-50mM or 10-100mM, preferably 5-50mM; (2) adding a lyoprotectant; and (3) freeze-drying to obtain a lyophilized preparation of the nucleic acid-lipid nanoparticle composition.
13. The method for preparing the nucleic acid-lipid nanoparticle composition according to claim 12, in, The lyoprotectant is selected from a combination of one or more of the group consisting of sucrose, trehalose, lactose, cyclodextrin and mannitol.
14. A method for preparing the nucleic acid-lipid nanoparticle composition according to claim 12 or 13, in, Based on the total weight of the freeze-dried preparation, the solid content of the freeze-dried protective agent is 50-99.9wt%.
15. The method for preparing the nucleic acid-lipid nanoparticle composition according to claim 14, in, Step (1) further comprises adding a buffer, wherein the content ratio of the buffer to lactate is 0.25-1:
1.
16. The method for preparing the nucleic acid-lipid nanoparticle composition according to claim 15, in, The buffer is a combination of one or more selected from the group consisting of acetate buffer, PBS buffer, citrate buffer, phosphate buffer, histidine buffer and tris buffer. Preferably, the buffer content is 1.25-50 mM.
17. A method for preparing a nucleic acid-lipid nanoparticle composition according to any one of claims 12 to 16, in, The pH of the solution obtained in step (1) is 1.0-14.0, such as 2.0-13.0, preferably 5.0-9.0, preferably 7.0-8.
0.
18. A method for preparing a nucleic acid-lipid nanoparticle composition according to any one of claims 12 to 17, in, The nucleic acid is selected from the group consisting of ssDNA, dsDNA, mRNA, lncRNA, siRNA, saRNA, shRNA, ASO, plasmid, circRNA, circDNA, miRNA, CRISPR-Cas, ployI:C, SamRNA and 5'-pppRNA.
19. A method for preparing a nucleic acid-lipid nanoparticle composition according to any one of claims 12 to 18, in, In step (1), the nucleic acid is encapsulated in lipid nanoparticles.
20. A method for preparing a nucleic acid-lipid nanoparticle composition according to any one of claims 12 to 19, in, The lipids include cationic lipids, neutral phospholipids, PEG-lipids and optionally steroidal lipids.
21. Use of the nucleic acid-lipid nanoparticle composition according to any one of claims 1 to 11 in the preparation of a drug.
22. The use according to claim 21, wherein the medicament is a vaccine.
23. The use according to claim 22, in, The vaccine is a vaccine for preventing cancer, a therapeutic tumor vaccine, a viral infection, a bacterial infection or a fungal infection.
24. The use according to claim 23, in, The virus is selected from the group consisting of Norovirus, Ebola virus, coronavirus, cytomegalovirus, dengue virus, Zika virus, enterovirus, hepatitis virus, herpes simplex virus, human papillomavirus, influenza virus, Marburg virus, measles virus, polio virus, rabies virus and rotavirus.
25. The use according to any one of claims 21 to 24, in, The medicine is an oral preparation, an intramuscular injection preparation, a subcutaneous injection preparation, an intravenous injection preparation or an inhalation preparation.
26. The use according to claim 25, in, The inhalation preparation is an aerosol inhalation preparation or a dry powder inhalation preparation.
Citation Information
Patent Citations
Lipid nanoparticle preparation and application thereof
CN112494424A
Lyophilization of nucleic acids in lactate-containing solutions
WO2011069587A1
LNP compositions comprising RNA and methods for preparing, storing and using the same
WO2022218503A1
Lipid compositions comprising peptide-lipid conjugates
WO2022235972A1
Cited By
Preparation method of lipid nanoparticle freeze-drying preparation
CN120241626A
A method of preparing a lipid nanoparticle lyophilized formulation
CN120241626B
